nach oben

Archives of Virology

Erschienen in:

30.11.2021 | Review

Evolution of the SARS-CoV-2 genome and emergence of variants of concern

verfasst von: Iman Safari, Elahe Elahi

Erschienen in: Archives of Virology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

The high transmission and mortality rates associated with SARS-CoV-2 have led to tragic consequences worldwide. Large-scale whole-genome sequencing of the SARS-CoV-2 genome since its identification in late 2019 has identified many sequence changes and the emergence of novel strains, each described by co-segregation of a particular set of sequence variations. Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern. A notable feature of the last four, each of which ultimately evolved from clade G, is the large number (≥ 20) of co-segregating sequence variations associated with them. Several variations are in the spike gene, and some variations are shared among or between strains. Meanwhile, observation of recurrent infections with the same or different SARS-CoV-2 lineages has raised concerns about the duration of the immune responses induced by the initial infection or the vaccine that was administered. While the alpha strain is sensitive to immune responses induced by earlier strains, the beta, gamma, and delta strains can escape antibody neutralization. Apart from random replication errors, intra-host RNA editing, chronic infections, and recombination are processes that may promote the accumulation of sequence changes in the SARS-CoV-2 genome. The known contribution of recombination to coronavirus evolution and recent data pertaining to SARS-CoV-2 suggest that recombination may be particularly important. Continued surveillance of the SARS-CoV-2 genome is imperative.

Nur mit Berechtigung zugänglich

Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265–269. https://doi.org/10.1038/s41586-020-2008-3CrossRefPubMedPubMedCentral

Zhou P, Lou YX, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. https://doi.org/10.1038/s41586-020-2012-7CrossRefPubMedPubMedCentral

Gorbalenya AE, Baker SC, Baric RS et al (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544. https://doi.org/10.1038/s41564-020-0695-zCrossRef

Su S, Wong G, Shi W et al (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24:490–502. https://doi.org/10.1016/j.tim.2016.03.003CrossRefPubMedPubMedCentral

Forni D, Cagliani R, Clerici M, Sironi M (2017) Molecular evolution of human coronavirus genomes. Trends Microbiol 25:35–48. https://doi.org/10.1016/j.tim.2016.09.001CrossRefPubMed

Ksiazek TG, Erdman D, Goldsmith CS et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:1953–1966. https://doi.org/10.1056/nejmoa030781CrossRefPubMed

Peiris JSM, Yuen KY, Osterhaus ADME, Stöhr K (2003) The severe acute respiratory syndrome. N Engl J Med 349:2431–2441. https://doi.org/10.1056/NEJMra032498CrossRefPubMed

De Wit E, Van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534. https://doi.org/10.1038/nrmicro.2016.81CrossRefPubMedPubMedCentral

Memish ZA, Perlman S, Van Kerkhove MD, Zumla A (2020) Middle East respiratory syndrome. Lancet 395:1063–1077. https://doi.org/10.1016/S0140-6736(19)33221-0CrossRefPubMedPubMedCentral

10.

Guan W, Ni Z, Hu Y et al (2020) Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/nejmoa2002032CrossRefPubMed

11.

World Health Organization (2020) WHO Director-General’s opening remarks at the media briefing on COVID-19-11 Mar 2020

12.

Hon C-C, Lam T-Y, Shi Z-L et al (2008) Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol 82:1819–1826. https://doi.org/10.1128/jvi.01926-07CrossRefPubMed

13.

Wang Y, Liu D, Shi W et al (2015) Origin and possible genetic recombination of the middle east respiratory syndrome coronavirus from the first imported case in china: phylogenetics and coalescence analysis. MBio. https://doi.org/10.1128/mBio.01280-15CrossRefPubMedPubMedCentral

14.

Zhang Z, Shen L, Gu X (2016) Evolutionary dynamics of MERS-CoV: potential recombination. Posit Sel Transm Sci Rep 6:25049. https://doi.org/10.1038/srep25049CrossRef

15.

Li X, Giorg EE, Marichannegowda MH et al (2020) Emergence of SARS-CoV-2 through recombination and strong purifying selection. Sci Adv 6:eabb9153. https://doi.org/10.1126/sciadv.abb9153CrossRefPubMedPubMedCentral

16.

Zhu Z, Meng K, Meng G (2020) Genomic recombination events may reveal the evolution of coronavirus and the origin of SARS-CoV-2. Sci Rep 10:1–10. https://doi.org/10.1038/s41598-020-78703-6CrossRef

17.

Forni D, Cagliani R, Sironi M (2020) Recombination and positive selection differentially shaped the diversity of betacoronavirus subgenera. Viruses 12:1313. https://doi.org/10.3390/v12111313CrossRefPubMedCentral

18.

Patiño-Galindo JÁ, Filip I, Rabadan R (2021) Global patterns of recombination across human viruses. Mol Biol Evol 38:2520–2531. https://doi.org/10.1093/molbev/msab046CrossRefPubMedPubMedCentral

19.

Bobay LM, O’Donnell AC, Ochman H (2020) Recombination events are concentrated in the spike protein region of Betacoronaviruses. PLoS Genet 16:e1009272. https://doi.org/10.1371/JOURNAL.PGEN.1009272CrossRefPubMedPubMedCentral

20.

Gribble J, Stevens LJ, Agostini ML et al (2021) The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog 17:e1009226. https://doi.org/10.1371/journal.ppat.1009226CrossRefPubMedPubMedCentral

21.

Duchene S, Featherstone L, Haritopoulou-Sinanidou M et al (2020) Temporal signal and the phylodynamic threshold of SARS-CoV-2. Virus Evol 6:veaa061. https://doi.org/10.1093/ve/veaa061CrossRefPubMedPubMedCentral

22.

Yan L, Yang Y, Li M et al (2021) Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading. Cell 184:3474-3485.e11. https://doi.org/10.1016/j.cell.2021.05.033CrossRefPubMedPubMedCentral

23.

Safari I, InanlooRahatloo K, Elahi E (2021) Evolution of SARS-CoV-2 genome from December 2019 to late March 2020: emerged haplotypes and informative Tag nucleotide variations. J Med Virol 93:2010–2020. https://doi.org/10.1002/jmv.26553CrossRefPubMed

24.

Tang X, Wu C, Li X et al (2020) On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 7:1012–1023. https://doi.org/10.1093/nsr/nwaa036CrossRefPubMedPubMedCentral

25.

Su YCF, Anderson DE, Young BE et al (2020) Discovery and genomic characterization of a 382-nucleotide deletion in ORF7B and orf8 during the early evolution of SARS-CoV-2. MBio 11:1–9. https://doi.org/10.1128/mBio.01610-20CrossRef

26.

Korber B, Fischer WM, Gnanakaran S et al (2020) Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182:812-827.e19. https://doi.org/10.1016/j.cell.2020.06.043CrossRefPubMedPubMedCentral

27.

Plante JA, Liu Y, Liu J et al (2021) Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592:116–121. https://doi.org/10.1038/s41586-020-2895-3CrossRefPubMed

28.

Safari I, InanlooRahatloo K, Elahi E (2021) World-wide tracking of major SARS-CoV-2 genome haplotypes in sequences of June 1 to November 15, 2020 and discovery of rapid expansion of a new haplotype. J Med Virol 93:3251–3256. https://doi.org/10.1002/jmv.26802CrossRefPubMed

29.

Yurkovetskiy L, Wang X, Pascal KE et al (2020) Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183:739-751.e8. https://doi.org/10.1016/j.cell.2020.09.032CrossRefPubMedPubMedCentral

30.

Volz E, Hill V, McCrone JT et al (2021) Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 184:64–75CrossRefPubMedPubMedCentral

31.

Lorenzo-Redondo R, Nam HH, Roberts SC et al (2020) A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways. EBioMedicine 62:103112. https://doi.org/10.1016/j.ebiom.2020.103112CrossRefPubMedPubMedCentral

32.

Tai W, He L, Zhang X et al (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17:613–620. https://doi.org/10.1038/s41423-020-0400-4CrossRefPubMedPubMedCentral

33.

Hu B, Guo H, Zhou P, Shi Z-L (2020) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19:141–154CrossRefPubMed

34.

Gobeil SMC, Janowska K, McDowell S et al (2021) D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction. Cell Rep 34:108630. https://doi.org/10.1016/j.celrep.2020.108630CrossRefPubMed

35.

Weissman D, Alameh MG, de Silva T et al (2021) D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe 29:23-31.e4. https://doi.org/10.1016/j.chom.2020.11.012CrossRefPubMed

36.

Zúñiga S, Sola I, Moreno JL et al (2007) Coronavirus nucleocapsid protein is an RNA chaperone. Virology 357:215–227. https://doi.org/10.1016/j.virol.2006.07.046CrossRefPubMed

37.

Zhao M, Yu Y, Sun LM et al (2021) GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein. Nat Commun 12:1–14. https://doi.org/10.1038/s41467-021-22297-8CrossRef

38.

Chen H, Cui Y, Han X et al (2020) Liquid–liquid phase separation by SARS-CoV-2 nucleocapsid protein and RNA. Cell Res 30:1143–1145. https://doi.org/10.1038/s41422-020-00408-2CrossRefPubMed

39.

Lu W, Zheng BJ, Xu K et al (2006) Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc Natl Acad Sci USA 103:12540–12545. https://doi.org/10.1073/pnas.0605402103CrossRefPubMedPubMedCentral

40.

Kern DM, Sorum B, Mali SS et al (2021) Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs. Nat Struct Mol Biol 28:573–582. https://doi.org/10.1038/s41594-021-00619-0CrossRefPubMedPubMedCentral

41.

Bianchi M, Borsetti A, Ciccozzi M, Pascarella S (2021) SARS-Cov-2 ORF3a: mutability and function. Int J Biol Macromol 170:820–826. https://doi.org/10.1016/j.ijbiomac.2020.12.142CrossRefPubMedPubMedCentral

42.

McCallum M, De Marco A, Lempp FA et al (2021) N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184:2332-2347.e16. https://doi.org/10.1016/j.cell.2021.03.028CrossRefPubMedPubMedCentral

43.

Rambaut A, Holmes EC, O’Toole Á et al (2021) Addendum: a dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 6:415. https://doi.org/10.1038/s41564-021-00872-5CrossRefPubMedPubMedCentral

44.

Fontanet A, Cauchemez S (2020) COVID-19 herd immunity: where are we? Nat Rev Immunol 20:583–584CrossRefPubMedPubMedCentral

45.

Wu J, Liang B, Chen C et al (2021) SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun 12:1–9. https://doi.org/10.1038/s41467-021-22034-1CrossRef

46.

Kang H, Wang Y, Tong Z, Liu X (2020) Retest positive for SARS-CoV-2 RNA of “recovered” patients with COVID-19: Persistence, sampling issues, or re-infection? J Med Virol 92:2263–2265. https://doi.org/10.1002/jmv.26114CrossRefPubMed

47.

To KK-W, Hung IF-N, Ip JD et al (2020) Coronavirus Disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome Coronavirus 2 strain confirmed by whole genome sequencing. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1275CrossRefPubMedPubMedCentral

48.

Brouqui P, Colson P, Melenotte C et al (2021) COVID-19 re-infection. Eur J Clin Invest 51:e13537. https://doi.org/10.1111/eci.13537CrossRefPubMedPubMedCentral

49.

Bongiovanni M (2021) COVID-19 reinfection in a healthcare worker. J Med Virol 93:4058–4059. https://doi.org/10.1002/jmv.26565CrossRefPubMed

50.

Ledford H (2020) COVID-19 reinfection: three questions scientists are asking. Nature 585:168–169CrossRefPubMed

51.

Lopez Bernal J, Andrews N, Gower C et al (2021) Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (delta) variant. N Engl J Med 385:585–594. https://doi.org/10.1056/NEJMoa2108891CrossRefPubMed

52.

Wise J (2020) Covid-19: New coronavirus variant is identified in UK. BMJ 371:m4857CrossRefPubMed

53.

Mahase E (2020) Covid-19: What have we learnt about the new variant in the UK? BMJ 371:m4944CrossRefPubMed

54.

Rambaut A, Loman N, Pybus O et al (2020) Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations—Virological. Virological.org, pp 1–9

55.

Tegally H, Wilkinson E, Giovanetti M et al (2021) Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592:438–443. https://doi.org/10.1038/s41586-021-03402-9CrossRefPubMed

56.

Voloch CM, da Silva FR, de Almeida LGP et al (2021) Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J Virol. https://doi.org/10.1128/jvi.00119-21CrossRefPubMedPubMedCentral

57.

Singh J, Rahman SA, Ehtesham NZ et al (2021) SARS-CoV-2 variants of concern are emerging in India. Nat Med 27:1131–1133. https://doi.org/10.1038/s41591-021-01397-4CrossRefPubMed

58.

Faria NR, Mellan TA, Whittaker C et al (2021) Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372:815–821CrossRefPubMedPubMedCentral

59.

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O’Toole ÁAR (2021) Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England enhanced reader.pdf. Nature 593:266–269. https://doi.org/10.1038/s41586-021-03470-xCrossRefPubMed

60.

Frampton D, Rampling T, Cross A et al (2021) Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis 3099:00170–00175. https://doi.org/10.1016/S1473-3099(21)00170-5CrossRef

61.

Davies NG, Abbott S, Barnard RC et al (2021) Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 3055:eabg3055. https://doi.org/10.1126/science.abg3055CrossRef

62.

Planas D, Bruel T, Grzelak L et al (2021) Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies. Nat Med 27:917–924. https://doi.org/10.1038/s41591-021-01318-5CrossRefPubMed

63.

Shen X, Tang H, McDanal C et al (2021) SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29:529-539.e3. https://doi.org/10.1016/j.chom.2021.03.002CrossRefPubMedPubMedCentral

64.

Muik A, Wallisch AK, Sänger B et al (2021) Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science 371:1152–1153. https://doi.org/10.1126/science.abg6105CrossRefPubMedPubMedCentral

65.

Wall EC, Wu M, Harvey R et al (2021) Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397:2331–2333. https://doi.org/10.1016/S0140-6736(21)01290-3CrossRefPubMedPubMedCentral

66.

Yadav PD, Sapkal G, Ella R et al (2021) Neutralization against B. 1.351 and B. 1.617. 2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv. https://doi.org/10.1101/2021.06.05.447177CrossRefPubMedPubMedCentral

67.

Edara VV, Norwood C, Floyd K et al (2021) Infection-and vaccine-induced antibody binding and neutralization of the B. 1.351 SARS-CoV-2 variant. Cell Host Microbe 29:516–521CrossRefPubMedPubMedCentral

68.

Rees-Spear C, Muir L, Griffith SA et al (2021) The effect of spike mutations on SARS-CoV-2 neutralization. Cell Rep 34:108890. https://doi.org/10.1016/j.celrep.2021.108890CrossRefPubMedPubMedCentral

69.

Shen X, Tang H, Pajon R et al (2021) Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. N Engl J Med 384:2352–2354. https://doi.org/10.1056/nejmc2103740CrossRefPubMed

70.

Wibmer CK, Ayres F, Hermanus T et al (2021) SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 27:622–625CrossRefPubMed

71.

Cele S, Gazy I, Jackson L et al (2021) Escape of SARS-CoV-2 501Y. V2 from neutralization by convalescent plasma. Nature 593:142–146CrossRefPubMed

72.

Abu-Raddad LJ, Chemaitelly H, Butt AA (2021) Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med 385:187–189. https://doi.org/10.1056/nejmc2104974CrossRefPubMed

73.

Dejnirattisai W, Zhou D, Supasa P et al (2021) Antibody evasion by the P. 1 strain of SARS-CoV-2. Cell 184:2939–2954CrossRefPubMedPubMedCentral

74.

Wang Z, Schmidt F, Weisblum Y et al (2021) mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592:616–622. https://doi.org/10.1038/s41586-021-03324-6CrossRefPubMedPubMedCentral

75.

Zhou D, Dejnirattisai W, Supasa P et al (2021) Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184:2348-2361.e6. https://doi.org/10.1016/j.cell.2021.02.037CrossRefPubMedPubMedCentral

76.

Hoffmann M, Arora P, Groß R et al (2021) SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184:2384-2393.e12. https://doi.org/10.1016/j.cell.2021.03.036CrossRefPubMedPubMedCentral

77.

Li Q, Nie J, Wu J et al (2021) SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell 184:2362-2371.e9. https://doi.org/10.1016/j.cell.2021.02.042CrossRefPubMedPubMedCentral

78.

Wang P, Nair MS, Liu L et al (2021) Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature 593:130–135. https://doi.org/10.1038/s41586-021-03398-2CrossRefPubMed

79.

Liu J, Liu Y, Xia H et al (2021) BNT162b2-elicited neutralization of B.1.61.7 and other SARS-CoV-2 variants. Nature. https://doi.org/10.1038/s41586-021-03693-yCrossRefPubMedPubMedCentral

80.

Shang J, Ye G, Shi K et al (2020) Structural basis of receptor recognition by SARS-CoV-2. Nature 581:221–224. https://doi.org/10.1038/s41586-020-2179-yCrossRefPubMedPubMedCentral

81.

Liu Y, Liu J, Plante KS et al (2021) The N501Y spike substitution enhances SARS-CoV-2 transmission. BioRxiv. https://doi.org/10.1101/2021.03.08.434499CrossRefPubMedPubMedCentral

82.

Tian F, Tong B, Sun L et al (2021) Mutation N501Y in RBD of spike protein strengthens the interaction between COVID-19 and its receptor ACE2. BioRxiv. https://doi.org/10.1101/2021.02.14.431117CrossRefPubMedPubMedCentral

83.

Nelson G, Buzko O, Spilman PR et al (2021) Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y. V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an esca. BioRxiv. https://doi.org/10.1101/2021.01.13.426558CrossRefPubMedPubMedCentral

84.

Weisblum Y, Schmidt F, Zhang F et al (2020) Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants. Elife 9:1. https://doi.org/10.7554/eLife.61312CrossRef

85.

Greaney AJ, Loes AN, Crawford KHD et al (2021) Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29:463-476.e6. https://doi.org/10.1016/j.chom.2021.02.003CrossRefPubMedPubMedCentral

86.

Jangra S, Ye C, Rathnasinghe R et al (2021) SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2:e283–e284. https://doi.org/10.1016/S2666-5247(21)00068-9CrossRefPubMedPubMedCentral

87.

Liu Z, VanBlargan LA, Bloyet L-M et al (2021) Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29:477–488CrossRefPubMedPubMedCentral

88.

Andreano E, Piccini G, Licastro D et al (2020) SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. https://doi.org/10.1101/2020.12.28.424451CrossRefPubMedPubMedCentral

89.

Brown JC, Goldhill DH, Zhou J et al (2021) Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape. bioRxiv. https://doi.org/10.1101/2021.02.24.432576CrossRefPubMedPubMedCentral

90.

Lubinski B, Tang T, Daniel S et al (2021) Functional evaluation of proteolytic activation for the SARS-CoV-2 variant B. 1.1.7: role of the P681H mutation. bioRxiv. https://doi.org/10.1101/2021.04.06.438731CrossRefPubMedPubMedCentral

91.

Peacock TP, Sheppard CM, Brown JC et al (2021) The SARS-CoV-2 variants associated with infections in India, B. 1.617, show enhanced spike cleavage by furin. bioRxiv. https://doi.org/10.1101/2021.05.28.446163CrossRef

92.

Li Q, Wu J, Nie J et al (2020) The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182:1284–1294CrossRefPubMedPubMedCentral

93.

Kemp BA, Papa SA, Datir G et al (2021) Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the variant of concern lineage B.1.1.7 Genomics UK (COG-UK) Consortium. Cell Rep 35:109292CrossRefPubMedPubMedCentral

94.

McCarthy KR, Rennick LJ, Nambulli S et al (2021) Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science 371:1139–1142. https://doi.org/10.1126/science.abf6950CrossRefPubMedPubMedCentral

95.

Lan J, Ge J, Yu J et al (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581:215–220. https://doi.org/10.1038/s41586-020-2180-5CrossRefPubMed

96.

Cottam EM, Whelband MC, Wileman T (2014) Coronavirus NSP6 restricts autophagosome expansion. Autophagy 10:1426–1441. https://doi.org/10.4161/auto.29309CrossRefPubMedPubMedCentral

97.

Benvenuto D, Angeletti S, Giovanetti M et al (2020) Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. J Infect 81:e24–e27. https://doi.org/10.1016/j.jinf.2020.03.058CrossRefPubMedPubMedCentral

98.

Grubaugh ND, Petrone ME, Holmes EC (2020) We shouldn’t worry when a virus mutates during disease outbreaks. Nat Microbiol 5:529–530CrossRefPubMed

99.

Choi B, Choudhary MC, Regan J et al (2020) Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 383:2291–2293CrossRefPubMed

100.

Baang JH, Smith C, Mirabelli C et al (2021) Prolonged severe acute respiratory syndrome Coronavirus 2 replication in an immunocompromised patient. J Infect Dis 223:23–27CrossRefPubMed

101.

Voloch CM, Ronaldo da Silva F, de Almeida LGP et al (2020) Intra-host evolution during SARS-CoV-2 persistent infection. medRxiv. https://doi.org/10.1101/2020.11.13.20231217CrossRef

102.

Kemp SA, Collier DA, Datir RP et al (2021) SARS-CoV-2 evolution during treatment of chronic infection. Nature 592:277–282. https://doi.org/10.1038/s41586-021-03291-yCrossRefPubMedPubMedCentral

103.

van Dorp L, Richard D, Tan CCS et al (2020) No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat Commun 11:1–8. https://doi.org/10.1038/s41467-020-19818-2CrossRef

104.

Yi H (2020) 2019 Novel coronavirus is undergoing active recombination. Clin Infect Dis 71:884–887. https://doi.org/10.1093/cid/ciaa219CrossRefPubMed

105.

Varabyou A, Pockrandt C, Salzberg SL, Pertea M (2021) Rapid detection of inter-clade recombination in SARS-CoV-2 with Bolotie. Genetics 218:iyab074. https://doi.org/10.1093/genetics/iyab074CrossRefPubMed

106.

Jackson B, Rambaut A, Pybus O et al (2021) Recombinant SARS-CoV-2 genomes involving lineage B.1.1.7 in the UK—Virological. In: Virological. https://virological.org/t/recombinant-sars-cov-2-genomes-involving-lineage-b-1-1-7-in-the-uk/658

107.

Sharma S, Patnaik SK, Thomas Taggart R et al (2015) APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages. Nat Commun 6:1–15. https://doi.org/10.1038/ncomms7881CrossRef

108.

Lamers MM, van den Hoogen BG, Haagmans BL (2019) ADAR1: “Editor-in-Chief” of cytoplasmic innate immunity. Front Immunol 10:1763. https://doi.org/10.3389/fimmu.2019.01763CrossRefPubMedPubMedCentral

109.

Hamilton CE, Papavasiliou FN, Rosenberg BR (2010) Diverse functions for DNA and RNA editing in the immune system. RNA Biol 7:220–228. https://doi.org/10.4161/rna.7.2.11344CrossRefPubMed

110.

Lai MMC, Cavanagh D (1997) The molecular biology of coronaviruses. Adv Virus Res 48:1–100CrossRefPubMedPubMedCentral

111.

Simon-Loriere E, Holmes EC (2011) Why do RNA viruses recombine? Nat Rev Microbiol 9:617–626. https://doi.org/10.1038/nrmicro2614CrossRefPubMedPubMedCentral

112.

Graham RL, Baric RS (2010) Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol 84:3134–3146. https://doi.org/10.1128/jvi.01394-09CrossRefPubMed

113.

Francisco RS, Benites LF, Lamarca AP et al (2021) Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul. Brazil. Virus Res 296:198345. https://doi.org/10.1016/j.virusres.2021.198345CrossRefPubMed

114.

Pedro N, Silva CN, Magalhães AC et al (2021) Dynamics of a dual sars-cov-2 lineage co-infection on a prolonged viral shedding COVID-19 case: Insights into clinical severity and disease duration. Microorganisms 9:1–10. https://doi.org/10.3390/microorganisms9020300CrossRef

115.

Taghizadeh P, Salehi S, Heshmati A et al (2021) Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains. Virology 562:63–73. https://doi.org/10.1016/j.virol.2021.06.004CrossRefPubMed

116.

VanInsberghe D, Neish AS, Lowen AC, Koelle K (2020) Identification of SARS-CoV-2 recombinant genomes. BioRxiv. https://doi.org/10.1101/2020.08.05.238386CrossRef

117.

Ignatieva A, Hein J, Jenkins PA (2021) Evidence of ongoing recombination in SARS-CoV-2 through genealogical reconstruction. BioRxiv. https://doi.org/10.1101/2021.01.21.427579CrossRef

118.

Moyo-Gwete T, Madzivhandila M, Makhado Z et al (2021) Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med 384:2161–2163. https://doi.org/10.1056/NEJMc2104192CrossRefPubMed

Titel: Evolution of the SARS-CoV-2 genome and emergence of variants of concern
verfasst von: Iman Safari
Elahe Elahi
Publikationsdatum: 30.11.2021
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 2/2022
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-021-05295-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

“Yaraviridae”: a proposed new family of viruses infecting Acanthamoeba castellanii

Complete genome sequencing and evolutionary analysis of hepatitis C virus subtype 6a, including strains from Guangdong Province, China

Recent molecular evolution of hepatitis B virus genotype F in Latin America

Comparison of the pathogenicity of porcine reproductive and respiratory syndrome virus (PRRSV)-1 and PRRSV-2 in pregnant sows

Complete genome sequence of a novel partitivirus infecting the phytopathogenic fungus Alternaria tenuissima